SCHEMBL7144534

SCHEMBL7144534

CCOC(=O)c1ccc(NC(=O)CNC(=O)[C@@H]2C[C@@H](SC(C)=O)CN2S(=O)(=O)c2ccc3ccccc3c2)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
POLB P06746 2/20 0.45
HTT P42858 1/20 0.45
MAPT P10636 4/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ADRB2 P07550 1/20 0.43
GAA P10253 1/20 0.43
MAPK1 P28482 1/20 0.41
CA9 Q16790 2/20 0.41
CA12 O43570 1/20 0.41
MME P08473 2/20 0.40
ACE P12821 2/20 0.40
ECE1 P42892 2/20 0.40
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39
CA2 P00918 1/20 0.39
PLAU P00749 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7141960 1.00 ALDH1A1 (0.45) ALDH1A1POLBHTTMAPTMEN1
SCHEMBL7145835 0.88 MME (0.53) ALDH1A1POLBHTTMAPTMEN1
SCHEMBL7145843 0.88 MME (0.53) ALDH1A1POLBHTTMAPTMEN1
SCHEMBL7143954 0.85 PLAU (0.43) ALDH1A1POLBMAPTGAAMAPK1
SCHEMBL7140041 0.83 MME (0.43) ALDH1A1POLBHTTMAPTKMT2A
SCHEMBL7140037 0.83 MME (0.43) ALDH1A1POLBHTTMAPTKMT2A
SCHEMBL7145969 0.81 PLAU (0.46) ALDH1A1POLBMAPTMEN1KMT2A
SCHEMBL7136798 0.81 MME (0.52) MAPTMEN1KMT2AADRB2GAA
SCHEMBL7151523 0.81 MME (0.52) MAPTMEN1KMT2AADRB2GAA
SCHEMBL7141707 0.80 MME (0.60) ALDH1A1HTTMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6541638-B2 (2S,4S)-1-(4-Mercapto-1-(naphthalene-2-sulfonyl)-pyrrolidine-2 -carbonyl)-piperidine-4-carboxylic acid ethyl ester for example; zinc protease inhibitors; for treating diseases associated with vasoconstriction HOFFMAN-LA ROCHE INC. 2003-04-01 US disclosed
US-20020049243-A1 Pyrrolidine derivatives HOFFMANN-LA ROCHE INC. 2002-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020049243-A1 Pyrrolidine derivatives PREP, PEPD, DNPEP ALDH1A1 767/4885POLB 1465/4885HTT 2147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.